Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2366-1089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia ; day:25 ; month:2 ; year:2021 ; pages:1-13
Oncology and Therapy ; (25.2.2021), 1-13
- Creator
-
Cook, Gordon C.
Corso, Alessandro
Streetly, Matthew
Mendeleeva, Larisa P.
Ptushkin, Vadim V.
Chan, Edmond
Ukropec, Jon
Iraqi, Wafae
Al-Akabawi, Assem
Pei, Huiling
Gaudig, Maren
Petrucci, Maria Teresa
Alegre, Adrian
Mateos, Maria-Victoria
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40487-020-00137-x
- URN
-
urn:nbn:de:101:1-2021051320030048505700
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cook, Gordon C.
- Corso, Alessandro
- Streetly, Matthew
- Mendeleeva, Larisa P.
- Ptushkin, Vadim V.
- Chan, Edmond
- Ukropec, Jon
- Iraqi, Wafae
- Al-Akabawi, Assem
- Pei, Huiling
- Gaudig, Maren
- Petrucci, Maria Teresa
- Alegre, Adrian
- Mateos, Maria-Victoria
- SpringerLink (Online service)
Other Objects (12)
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Daratumumab monotherapy for refractory lupus nephritis
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Daratumumab monotherapy for refractory lupus nephritis
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
Daratumumab monotherapy for refractory lupus nephritis
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease